A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration | Zendy

Chirag P. Shah | Zendy; Ramandeep Singh | Zendy; Rohan Chauhan | Zendy; Ashish Saxena | Zendy; Anup Shah | Zendy; Laxshmi Mondal | Zendy; Dhananjay Bakhle | Zendy; Arpit Shah | Zendy; Shashank Deoghare | Zendy; Neelakant Krishnan | Zendy; Neelima Godse | Zendy

Open Access

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration

Author(s) -

Chirag P. Shah,

Ramandeep Singh,

Rohan Chauhan,

Ashish Saxena,

Anup Shah,

Laxshmi Mondal,

Dhananjay Bakhle,

Arpit Shah,

Shashank Deoghare,

Neelakant Krishnan,

Neelima Godse

Publication year - 2022

Publication title -

indian journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.542

H-Index - 51

eISSN - 1998-3689

pISSN - 0301-4738

DOI - 10.4103/ijo.ijo_2118_21

Subject(s) - medicine , ranibizumab , macular degeneration , immunogenicity , ophthalmology , double blind , prospective cohort study , randomized controlled trial , bevacizumab , surgery , antibody , chemotherapy , immunology , alternative medicine , pathology , placebo

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research